References
Cisneros JM, Rodriguez-Bano J (2002) Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 8:687–693
Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, Rosenzweig R, Gutmann L, Safar M, Acar J (1995) Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 20:790–796
Manikal VM, Landman D, Suarina G, Oydna E, Lal H, Quale J (2000) Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31:101–106
National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 6th edn. Supplemental tables. NCCLS, Wayne, PA
Eliopoulos GM, Moellering RC Jr (1996) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, MD, pp 330–397
Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239
Gales AC, Reis AO, Jones RN (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183–190
Quale J, Bratu S, Landman D, Heddurshetti R (2003) Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 37:214–220
Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H (2001) Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40:117–120
Fernandez-Cuenca F, Martinez-Martinez L, Pascual A, Perea EJ (2003) In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin, or imipenem against clinical isolates of Acinetobacter baumannii. Chemotherapy 49:24–26
Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S (2002) Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. Arch Intern Med 162:1515–1520
Rodriguez-Hernandez MJ, Pachon J, Pichardo C, Cuberos L, Ibanez-Martinez J, Garcia-Curiel A, Caballero FJ, Moreno I, Jimenez-Mejias ME (2000) Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45:493–501
Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ (2004) In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48:753–757
Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M (2003) Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 22:28–34
Bonapace CR, White RL, Friedrich LV, Bosso JA (2000) Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E-test, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 38:43–50
Acknowledgements
This study was presented in part at the 41st annual meeting of the Infectious Diseases Society of America (IDSA), San Diego, CA, USA, October 9–12, 2003
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haddad, F.A., Van Horn, K., Carbonaro, C. et al. Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis 24, 577–579 (2005). https://doi.org/10.1007/s10096-005-1366-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-005-1366-y